Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ioannis Dardalas"'
Autor:
Theofanis Vavilis, Eleni Stamoula, Alexandra Ainatzoglou, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Ioannis S. Vizirianakis
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 166 (2023)
Protein replacement therapy is an umbrella term used for medical treatments that aim to substitute or replenish specific protein deficiencies that result either from the protein being absent or non-functional due to mutations in affected patients. Tr
Externí odkaz:
https://doaj.org/article/0622ec555ecb43cd879022321d2564ae
Autor:
Eleni Stamoula, Spyridon Siafis, Ioannis Dardalas, Alexandra Ainatzoglou, Alkis Matsas, Theodoros Athanasiadis, Chrysanthi Sardeli, Konstantinos Stamoulas, Georgios Papazisis
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundIncreased prevalence of depression has been observed among patients with multiple sclerosis (MS) and correlated with the elevated levels of proinflammatory cytokines and the overall deregulation of monoaminergic neurotransmitters that these
Externí odkaz:
https://doaj.org/article/85ca8b0f6b52455480cbe824a1e3fa7c
Autor:
Georgios Papazisis, Еleni Stamoula, Alexandra Ainatzoglou, Ioannis Dardalas, Theofanis Vavilis, Vasileios-Periklis Stamatellos, Spyridon Siafis, Thomas Psathas, Ioanna Boskou
Publikováno v:
CNS & Neurological Disorders - Drug Targets. 22
Background: Multiple sclerosis (MS) is a lifelong deteriorating disease characterized by multiple heterogeneous symptoms. Being an autoimmune disease of the central nervous system, mainly affecting the myelin sheath of the nerves ordinarily results i
Publikováno v:
Current Pharmaceutical Design. 27:2387-2397
Background: Multiple sclerosis (MS) is a chronic inflammatory and immune-mediated disease, whose current therapeutic means are mostly effective in the relapsing-remitting form of MS, where inflammation is still prominent, but fall short of preventing
Autor:
Eleni Stamoula, Eleana Sarantidi, Vasilis Dimakopoulos, Alexandra Ainatzoglou, Ioannis Dardalas, Georgios Papazisis, Konstantina Kontopoulou, Athanasios K. Anagnostopoulos
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 17; Pages: 10153
Over the course of the pandemic, proteomics, being in the frontline of anti-COVID-19 research, has massively contributed to the investigation of molecular pathogenic properties of the virus. However, data on the proteome on anti-SARS-CoV-2 vaccinated
Autor:
Theofanis Vavilis, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas, Georgios Papazisis
Publikováno v:
European Journal of Pharmacology. 944:175587
Autor:
Chryssa Pourzitaki, Dimitrios Kouvelas, Frideriki Poutoglidou, Ioannis Dardalas, Vasilios K. Kimiskidis
Publikováno v:
CNS & Neurological Disorders - Drug Targets. 19:220-226
Background: Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that is being actively explored as a potential therapeutic modality in various neuropsychiatric disorders, such as depression, neuropathic p
Autor:
Ioannis Vizirianakis, Malamatenia Lamprinou, Alexandra Ainatzoglou, ELENI STAMOULA, Ioannis Dardalas, Theofanis Vavilis, Athanasios Sachinidis
Publikováno v:
Pharmaceutics. 15:166
Protein replacement therapy is an umbrella term used for medical treatments that aim to substitute or replenish specific protein deficiencies that result either from the protein being absent or non-functional due to mutations in affected patients. Tr
Autor:
Εleni Stamoula, Alexandra Ainatzoglou, Vasileios-Periklis Stamatellos, Ioannis Dardalas, Spyridon Siafis, Alkis Matsas, Konstantinos Stamoulas, Georgios Papazisis
Publikováno v:
Multiple sclerosis and related disorders. 58
The high efficacy of atypical antipsychotics (AAP) in treating diverse psychiatric disorders has been partly attributed to their capacity to curb neuroinflammation, a shared aspect of these diseases. These immunomodulatory properties of AAP have late
Autor:
Alkis Matsas, Ioannis Dardalas, Spyridon Siafis, Chrysanthi Sardeli, Alexandra Ainatzoglou, Eleni Stamoula, Konstantinos G. Stamoulas, Georgios Papazisis, Theodoros Athanasiadis
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundIncreased prevalence of depression has been observed among patients with multiple sclerosis (MS) and correlated with the elevated levels of proinflammatory cytokines and the overall deregulation of monoaminergic neurotransmitters that these